1. Home
  2. UTG vs ARQT Comparison

UTG vs ARQT Comparison

Compare UTG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UTG

Reaves Utility Income Fund of Beneficial Interest

HOLD

Current Price

$37.08

Market Cap

3.3B

Sector

Finance

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$29.74

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTG
ARQT
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
UTG
ARQT
Price
$37.08
$29.74
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.83
AVG Volume (30 Days)
317.8K
2.3M
Earning Date
01-01-0001
10-28-2025
Dividend Yield
7.28%
N/A
EPS Growth
N/A
N/A
EPS
9.86
N/A
Revenue
$96,107,593.00
$317,929,000.00
Revenue This Year
N/A
$85.51
Revenue Next Year
N/A
$30.74
P/E Ratio
$3.20
N/A
Revenue Growth
8.35
129.21
52 Week Low
$25.26
$11.13
52 Week High
$35.29
$31.77

Technical Indicators

Market Signals
Indicator
UTG
ARQT
Relative Strength Index (RSI) 43.82 59.80
Support Level $37.04 $28.95
Resistance Level $38.00 $31.77
Average True Range (ATR) 0.71 1.36
MACD 0.06 -0.14
Stochastic Oscillator 46.75 54.51

Price Performance

Historical Comparison
UTG
ARQT

About UTG Reaves Utility Income Fund of Beneficial Interest

Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: